Maxigen Biotech Inc. (TWSE: 1783)
Health Care · Biotechnology · TW
NT$38.10
+2.83% today · -14.1% 1Y
Maxigen Biotech Inc. (TWSE: 1783) operates in the Biotechnology industry within the Health Care sector. The company is valued at $106.88M and employs 127 people.
Over the last twelve months the share price has lost 14.1%, trading between 36.10 and 48.30.
Tweenvest scores Maxigen Biotech Inc. across four factors: quality 93/100, value 87/100, dividend 47/100. Its strongest factor is quality.
1783 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $106.88M
- Revenue (TTM)
- $26.32M
- P/E
- 11.84
- EPS
- 3.22
- Dividend yield
- 5.25%
- Beta (5Y)
- 0.36
- 52-week high
- NT$48.30
- 52-week low
- NT$36.10
- Avg volume (3M)
- —
- Shares outstanding
- 89.70M
- Employees
- 127
- Next earnings
- —
About Maxigen Biotech Inc.
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
- ISIN
- TW0001783009
- Founded
- 1998
- Listed since
- Oct 3, 2012
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharmosa Biopharm Inc.TPEX: 6875 | $109.08M | NT$27.00 | -9.70% |
| Immunic, Inc.NasdaqCM: IMUX | $108.47M | $6.92 | -13.02% |
| Humacyte, Inc.NasdaqGS: HUMA | $108.23M | $0.36 | -7.65% |
| Tenax Therapeutics, Inc.NasdaqCM: TENX | $107.12M | $1.63 | -13.10% |
| Tevogen Inc.NasdaqGM: TVGN | $106.69M | $7.15 | +5.46% |
| Vaxart, Inc.OTCPK: VXRT | $105.65M | $0.43 | -0.59% |
| BioGend Therapeutics Co., Ltd.TPEX: 6733 | $104.60M | NT$24.90 | -0.80% |
| Paradigm Biopharmaceuticals LimitedASX: PAR | $104.36M | AU$— | — |
Figures last refreshed Oct 11, 2026.